Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its revenue outlook and market share growth during a specific period [1][3]. Company Overview - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [2]. Allegations of the Lawsuit - The lawsuit claims that Boston Scientific and its executives made false or misleading statements about the company's revenue projections and growth potential, particularly in the Electrophysiology market, where new competition has impacted its market share [3]. - Specific allegations include the failure to disclose risks related to seasonality and macroeconomic fluctuations, which contributed to an overly optimistic portrayal of the company's growth trajectory [3]. Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, revealing a GAAP net income of $672 million or $0.45 per share for Q4 2025, an increase from $566 million or $0.38 per share a year prior [4]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, compared to $1.853 billion or $1.25 per share the previous year, with adjusted EPS rising to $3.06 from $2.51 [4]. - The reported EPS for Q4 was below the company's guidance range of $0.48 to $0.52, leading to a stock price drop of over 17% following the announcement [4]. Legal Process - Investors who purchased Boston Scientific common stock during the class period have until May 4, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [6].

Core Insights - Boston Scientific Corporation (BSX) is a leading medical device company with a market cap of $140.4 billion, focusing on various interventional medical specialties globally [1] Financial Performance - Analysts expect BSX to report a profit of $0.78 per share for Q4 2025, reflecting an 11.4% increase from $0.70 per share in the same quarter last year [2] - For the full fiscal year 2025, BSX is projected to achieve an EPS of $3.04, which is a 21.1% increase from $2.51 in fiscal 2024 [3] - The EPS is anticipated to rise further to $3.45 in fiscal 2026, marking a year-over-year growth of 13.5% [3] Stock Performance - Over the past 52 weeks, BSX stock has increased by 7.2%, underperforming the S&P 500 Index, which gained 17.1%, and the Health Care Select Sector SPDR Fund, which returned 14.3% [4] - Following the Q3 results announcement on October 22, 2025, BSX shares rose by 4%, with an adjusted EPS of $0.75 exceeding Wall Street's expectation of $0.71 and revenue reaching $5.1 billion, surpassing forecasts of $5 billion [5] Analyst Ratings - The consensus opinion among analysts is bullish, with a "Strong Buy" rating for BSX stock; 26 out of 31 analysts recommend a "Strong Buy," while three suggest a "Moderate Buy" and two give a "Hold" [6] - The average analyst price target for BSX is $126.80, indicating a potential upside of 28.5% from current levels [6]